Valuation: Cytokinetics, Incorporated

Market Cap 8.52B 7.63B 7.04B 6.37B 11.91B 811B 12.11B 83.99B 33.51B 425B 31.97B 31.29B 1,345B P/E 2026 *
-10.1x
P/E 2027 * -13.3x
Enterprise Value 7.36B 6.59B 6.08B 5.5B 10.29B 701B 10.45B 72.53B 28.94B 367B 27.61B 27.02B 1,161B EV / Sales 2026 *
47.1x
EV / Sales 2027 * 17.4x
Free-Float
98.21%
Yield 2026 *
-
Yield 2027 * -
1 day+3.17%
1 week+0.69%
Current month-4.78%
1 month-4.39%
3 months-19.93%
6 months+5.34%
Current year-1.23%
1 week 60.14
Extreme 60.145
63.95
1 month 59.78
Extreme 59.785
67.27
Current year 58.43
Extreme 58.43
88.31
1 year 58.05
Extreme 58.05
88.31
3 years 29.31
Extreme 29.31
110.25
5 years 25.98
Extreme 25.98
110.25
10 years 5.75
Extreme 5.75
110.25
Manager TitleAgeSince
Chief Executive Officer 62 2006-12-31
Director of Finance/CFO 55 2024-05-07
Chief Operating Officer - 2018-02-28
Director TitleAgeSince
Director/Board Member 62 2006-12-31
Chairman 81 2022-04-07
Director/Board Member 78 2011-02-08
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Exercice

Chief Executive Officer

22,500 0.0162%
10/6/26 Exercice

Chief Technology Officer

10,500 0.0076%
9/28/26 Exercice

Chief Executive Officer

22,500 0.0162%
Change 5-day change 1-year change 3-year change Capi.($)
+3.19%+0.69%+1.24%+95.57% 8.52B
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-1.84%-1.66%+25.64%+54.49% 45.99B
-0.67%-3.38%+17.31%+97.93% 42.45B
+0.59%+0.23%+224.23%+925.18% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.08%+3.19%+46.86%+155.36% 40.11B
Weighted average by Cap. -0.11%+3.01%+48.01%+158.36%

Financials

2026 *2027 *
Net sales 156M 140M 129M 117M 219M 14.89B 222M 1.54B 615M 7.79B 587M 574M 24.68B 429M 384M 354M 320M 599M 40.81B 609M 4.23B 1.69B 21.36B 1.61B 1.57B 67.65B
Net income -805M -721M -665M -602M -1.13B -76.62B -1.14B -7.93B -3.16B -40.1B -3.02B -2.96B -127B -652M -584M -539M -487M -911M -62.06B -926M -6.43B -2.56B -32.48B -2.45B -2.39B -103B
Net Debt -1.16B -1.04B -960M -869M -1.62B -111B -1.65B -11.46B -4.57B -57.91B -4.36B -4.27B -183B -1.06B -953M -879M -795M -1.49B -101B -1.51B -10.49B -4.18B -53B -3.99B -3.91B -168B
Projected Income Statement - Annual - Cytokinetics, Incorporated
Logo Cytokinetics, Incorporated
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Employees
673
Date Price Change Volume
26-10-29 US$62.76 +2.42% 902,607
26-10-28 US$61.28 -0.39% 1,274,169
26-10-27 US$61.52 +1.30% 1,148,268
26-10-26 US$60.73 -0.82% 783,238
26-10-23 US$61.23 -1.76% 985,632
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cytokinetics, Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
61.28USD
Average target price
109.20USD
Spread / Average Target
+78.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cytokinetics, Incorporated
  1. Stock Market
  2. Stocks
  3. CYTK Stock